Companies › JW Pharmaceutical
7 active drug programs in 16 registered trials: 9 Phase 4, 3 Phase 1, 3 Phase 3, 1 Phase 2; Metabolic and endocrine, Other, Cardiovascular, Genitourinary; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Pitavastatin HMG-CoA reductase inhibitor | HMGCR | Phase 4 | Hypercholesterolemia; Dyslipidemias; ASCVD; Primary Prevention … | Nov 2026 |
| Anagliptin Dipeptidyl peptidase IV inhibitor | DPP4 | Phase 4 | Type 2 Diabetes Mellitus (T2DM) | Mar 2027 |
| Empagliflozin Sodium/glucose cotransporter 2 inhibitor | SLC5A2 | Phase 4 | Type 2 Diabetes Mellitus (T2DM) | Mar 2027 |
| Linzagolix (KLH-2109) Gonadotropin-releasing hormone receptor antagonist | GNRHR | Phase 3 | Menorrhagia | Mar 2028 |
| JW0104+C2402 | – | Phase 3 | Hypertension | – |
| JW0061 | – | Phase 1 | Healthy | Dec 2026 |
| JW2286 | – | Phase 1 | Healthy | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05537948 | Pitavastatin | Phase 4 | Dyslipidemias | Metabolic and endocrine | Jan 2024 |
| NCT06703710 | JW2286 | Phase 1 | Healthy | Other | Nov 2025 |
| NCT06643130 | JW0104+C2402 | Phase 3 | Hypertension | Cardiovascular | Apr 2026 |
| NCT06643130 | JW0104+C2402 | Phase 3 | Hypertension | Cardiovascular | Apr 2026 |
| NCT07442630 | Pitavastatin | Phase 4 | Hypercholesterolemia | Metabolic and endocrine | Nov 2026 |
| NCT07442630 | Pitavastatin | Phase 4 | Hypercholesterolemia | Metabolic and endocrine | Nov 2026 |
| NCT07514780 | JW0061 | Phase 1 | Healthy | Other | Dec 2026 |
| NCT07549958 | Pitavastatin | Phase 1 | Pancreatic Cancer | Oncology | Mar 2027 |
| NCT07442006 | Empagliflozin | Phase 4 | Type 2 Diabetes Mellitus (T2DM) | Metabolic and endocrine | Mar 2027 |
| NCT07442006 | Empagliflozin | Phase 4 | Type 2 Diabetes Mellitus (T2DM) | Metabolic and endocrine | Mar 2027 |
| NCT07442006 | Anagliptin | Phase 4 | Type 2 Diabetes Mellitus (T2DM) | Metabolic and endocrine | Mar 2027 |
| NCT07460960 | Pitavastatin | Phase 2 | Erectile Dysfunction Due to Arterial Disease | Cardiovascular | Dec 2027 |
| NCT07378098 | Linzagolix (KLH-2109) | Phase 3 | Menorrhagia | Genitourinary | Mar 2028 |
| NCT06767774 | Pitavastatin | Phase 4 | ASCVD | Metabolic and endocrine | Aug 2029 |
| NCT06722521 | Pitavastatin | Phase 4 | Primary Prevention | Cardiovascular | Jun 2032 |
| NCT06722521 | Pitavastatin | Phase 4 | Primary Prevention | Cardiovascular | Jun 2032 |
Shenzhen Salubris Pharmaceuticals Boryung Pharmaceutical CSPC Ouyi Pharmaceutical Shanghai Minwei Biotechnology Beijing QL Biopharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.